Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Martin Wilson Sells 12,253 Shares

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson sold 12,253 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,557.43. Following the transaction, the general counsel owned 683,376 shares of the company’s stock, valued at $2,261,974.56. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rocket Pharmaceuticals Price Performance

Shares of RCKT opened at $3.45 on Thursday. The firm has a market capitalization of $373.36 million, a price-to-earnings ratio of -1.53 and a beta of 0.48. The firm’s fifty day simple moving average is $3.49 and its 200-day simple moving average is $3.39. Rocket Pharmaceuticals, Inc. has a twelve month low of $2.19 and a twelve month high of $11.09. The company has a current ratio of 7.30, a quick ratio of 7.30 and a debt-to-equity ratio of 0.06.

Hedge Funds Weigh In On Rocket Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Federated Hermes Inc. increased its holdings in shares of Rocket Pharmaceuticals by 0.5% in the 3rd quarter. Federated Hermes Inc. now owns 627,567 shares of the biotechnology company’s stock valued at $2,046,000 after acquiring an additional 3,264 shares during the period. Barclays PLC grew its holdings in shares of Rocket Pharmaceuticals by 2.4% during the fourth quarter. Barclays PLC now owns 153,049 shares of the biotechnology company’s stock worth $537,000 after buying an additional 3,656 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Rocket Pharmaceuticals by 1.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 309,247 shares of the biotechnology company’s stock valued at $1,085,000 after acquiring an additional 3,809 shares during the period. CANADA LIFE ASSURANCE Co increased its position in Rocket Pharmaceuticals by 94.4% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 5,926 shares during the period. Finally, Rockefeller Capital Management L.P. lifted its position in Rocket Pharmaceuticals by 7.3% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 96,982 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 6,580 shares during the period. 98.39% of the stock is currently owned by hedge funds and other institutional investors.

Rocket Pharmaceuticals News Roundup

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: Morgan Stanley flagged Rocket as a potential beneficiary of a 2026 biotech-sector recovery, highlighting the company among small-to-mid cap names that could outperform (despite lowering its price target from $7 to $5 and keeping an Equal Weight rating). This note can attract buyer interest on hopes of sector-wide momentum. Morgan Stanley Names Rocket Pharmaceuticals as Key Beneficiary
• Neutral Sentiment: Rocket is expected to report quarterly earnings on Thursday; the upcoming release is a near-term catalyst that could increase volatility depending on revenue, guidance, or pipeline updates. Investors often trade cautiously into earnings. Rocket Pharmaceuticals Expected to Announce Quarterly Earnings
• Negative Sentiment: Several insiders sold stock on Feb. 13 (CEO Gaurav Shah sold 12,279 shares at an average $3.31; General Counsel Martin Wilson and director John Militello also reported sales). Multiple Form 4s reduce insider ownership modestly and can be interpreted negatively by investors sensitive to insider activity. Gaurav Shah Form 4 (SEC)

Analysts Set New Price Targets

RCKT has been the subject of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and set a $16.00 price target on shares of Rocket Pharmaceuticals in a report on Friday, November 7th. TD Cowen raised Rocket Pharmaceuticals to a “hold” rating in a research report on Friday, December 19th. Morgan Stanley set a $5.00 target price on Rocket Pharmaceuticals in a research note on Thursday, January 8th. Bank of America dropped their price target on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, JPMorgan Chase & Co. cut shares of Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Tuesday, November 18th. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $14.36.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.